The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents, Adv Drug Deliv Rev, vol.77, pp.3-11, 2014. ,
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy, Clin Pharmacokinet, vol.46, issue.12, pp.997-1038, 2007. ,
Insufficient ?-lactam concentrations in the early phase of severe sepsis and septic shock, Crit Care Lond Engl, vol.14, issue.4, p.126, 2010. ,
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients, Clin Pharmacokinet, vol.50, issue.2, pp.99-110, 2011. ,
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of ?-lactams, Crit Care Lond Engl, vol.15, issue.5, p.206, 2011. ,
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, vol.34, issue.6, pp.1589-96, 2006. ,
Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia, Chest, 2002. ,
Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome, Crit Care Med, vol.31, issue.2, pp.462-469, 2003. ,
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR), Crit Care Lond Engl, vol.23, issue.1, p.104, 2019. ,
Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials, Am J Respir Crit Care Med, vol.15, issue.6, pp.681-91, 2016. ,
Prolonged versus Intermittent Infusion of ?-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother, vol.48, pp.81-90, 2016. ,
Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis, Eur J Drug Metab Pharmacokinet, vol.43, issue.2, pp.155-70, 2018. ,
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers, Antimicrob Agents Chemother, vol.49, issue.5, pp.1881-1890, 2005. ,
Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model, Antimicrob Agents Chemother, vol.38, issue.5, pp.931-937, 1994. ,
Preparing and administering injectable antibiotics: How to avoid playing God, Med Mal Infect, 2016. ,
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections, Antimicrob Agents Chemother, vol.51, issue.5, pp.1725-1755, 2007. ,
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo, Antimicrob Agents Chemother, vol.51, issue.9, pp.3449-51, 2007. ,
Elevated ?-lactam concentrations associated with neurological deterioration in ICU septic patients, Minerva Anestesiol, vol.81, issue.5, pp.497-506, 2015. ,
Prospective monitoring of cefepime in intensive care unit adult patients, Crit Care Lond Engl, vol.14, issue.2, p.51, 2010. ,
Continuous epileptiform discharges in patients treated with cefepime or meropenem, Arch Neurol, vol.68, issue.10, pp.1303-1310, 2011. ,
Simultaneous Determination of 12 ?-Lactam Antibiotics in Human Plasma by High-Performance Liquid Chromatography with UV Detection: Application to Therapeutic Drug Monitoring, Antimicrob Agents Chemother, vol.55, issue.10, pp.4873-4882, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00875271
Simultaneous Determination of Eight ?-Lactam Antibiotics, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection, vol.60, pp.4734-4776, 2016. ,
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort, J Antimicrob Chemother, vol.71, issue.1, pp.196-207, 2016. ,
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care, vol.14, pp.390-396, 2008. ,
Continuous infusion versus intermittent administration of meropenem in critically ill patients, J Antimicrob Chemother, vol.43, issue.4, pp.523-530, 1999. ,
Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study, J Crit Care, vol.52, pp.75-84, 2019. ,
Prospective determination of serum ceftazidime concentrations in intensive care units, Ther Drug Monit, 2010. ,
Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion, Int J Antimicrob Agents, vol.41, issue.5, pp.434-442, 2013. ,
Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of ?-lactams administered by continuous infusion: a prospective observational study, Int J Antimicrob Agents, vol.51, issue.3, pp.443-452, 2018. ,
Augmented renal clearance and therapeutic monitoring of ?-lactams, Int J Antimicrob Agents, vol.45, issue.4, pp.331-334, 2015. ,
fdadrug-safety-communication-cefepime-and-risk-seizure-patients-not-receiving-dosageadjustments 34. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient, Crit Care Med, vol.37, issue.3, pp.840-51, 2009. ,
Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients, Int J Antimicrob Agents, vol.48, issue.4, pp.435-444, 2016. ,
The clinical relevance of plasma protein binding changes ,
, Clin Pharmacokinet, vol.52, issue.1, pp.1-8, 2013.
Protein binding of ?-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?, Antimicrob Agents Chemother, vol.57, issue.12, pp.6165-70, 2013. ,
Changes in plasma protein binding have little clinical relevance, Clin Pharmacol Ther, vol.71, issue.3, pp.115-136, 2002. ,
Cefepime-induced neurotoxicity: a systematic review. Crit Care Lond Engl, vol.21, p.276, 2017. ,
,
, Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.23, issue.7, pp.454-463, 2017.
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function, Antimicrob Agents Chemother, vol.54, issue.10, pp.4360-4367, 2010. ,
Risk factors for target non-attainment during empirical treatment with ?-lactam antibiotics in critically ill patients, Intensive Care Med, vol.40, issue.9, pp.1340-51, 2014. ,
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept, Int J Antimicrob Agents, vol.36, issue.4, pp.332-341, 2010. ,
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care, vol.2, p.35, 2012. ,
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial, Intensive Care Med, vol.40, issue.3, pp.380-387, 2014. ,
Impact of ?-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy, Int J Antimicrob Agents, vol.49, issue.5, pp.589-94, 2017. ,
Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study, Ther Drug Monit, vol.34, issue.2, pp.160-164, 2012. ,
Daily serum piperacillin monitoring is advisable in critically ill patients, Int J Antimicrob Agents, vol.35, issue.5, pp.500-503, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00578296
Neurological Adverse Effects Attributable to ?-Lactam Antibiotics: A Literature Review, Drug Saf, vol.40, issue.12, pp.1171-98, 2017. ,
Cefepime-induced encephalopathy with triphasic waves in three Asian patients, Ann Acad Med, vol.36, issue.6, pp.450-451, 2007. ,
Association of antibiotics with status epilepticus ,
, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.34, issue.3, pp.327-358, 2013.
,
, Multicenter Randomized Trial of Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis, Am J Respir Crit Care Med, vol.192, issue.11, pp.1298-305, 201501.
Cefepime pharmacodynamics in patients with extended spectrum ?-lactamase (ESBL) and non-ESBL infections, J Infect, vol.54, issue.5, pp.463-471, 2007. ,
DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic, BMC Infect Dis, vol.12, p.152, 2012. ,
BetaLactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, vol.42, issue.10, pp.1535-1580, 2016. ,
, Lactams continuous infusion in intensive care unit patients : target attainment, variability factors and therapeutic drug monitoring
, Covariates associated with target attainment in patient presented dosage adjustment or not Supplementary Figure 1: Percentage of patient normodosed, overdosed or underdosed at D1, D4 and D7 for documented infections : a) cefepime, n= 82, b) ceftazidime, n=64, c) cefotaxime, n=113 and d) meropenem, vol.5, p.50
, Supplementary Figure 2 : Evolution of patients underdosed, normodosed and overdosed at D1, D4 and D7, owing to dosage adjustment ?? or not
, Bibliographie 1. Surveillance de la consommation des antibiotiques / 2018 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil [Internet, vol.8, pp.5-12, 2013.
Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care, Minerva Anestesiol, vol.76, issue.7, pp.509-533, 2010. ,
Pharmacokinetic issues for antibiotics in the critically ill patient, Crit Care Med, vol.37, issue.3, pp.840-51, 2009. ,
Antibiotic resistance--what's dosing got to do with it? Crit Care Med, vol.36, pp.2433-2473, 2008. ,
Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR), Crit Care Lond Engl, vol.23, issue.1, p.104, 2019. ,
Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials, Am J Respir Crit Care Med, 2016. ,
Prolonged versus Intermittent Infusion of ?-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother, vol.48, pp.81-90, 2016. ,
Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis, Eur J Drug Metab Pharmacokinet, 2018. ,
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort, J Antimicrob Chemother, vol.71, issue.1, pp.196-207, 2016. ,
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection, J Antimicrob Chemother, vol.61, issue.2, pp.382-390, 2008. ,
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers, Antimicrob Agents Chemother, vol.49, issue.5, pp.1881-1890, 2005. ,
Insufficient ?-lactam concentrations in the early phase of severe sepsis and septic shock, Crit Care Lond Engl, vol.14, issue.4, p.126, 2010. ,
Neurotoxic effects associated with antibiotic use: management considerations, Br J Clin Pharmacol, vol.72, issue.3, pp.381-93, 2011. ,
Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside, Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol, vol.24, issue.10, pp.649-53, 2005. ,
, Axepim® et ses génériques) : rappel des risques d'effets indésirables neurologiques graves lors du non-respect des posologies recommandées notamment en cas d'insuffisance rénale -Lettre aux professionnels de santé -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database, J Neurol Sci, 2019. ,
Encéphalopathies médicamenteuses, une approche pratique pour le clinicien. Prat Neurol -FMC, vol.5, pp.39-48, 2014. ,
Neurological Adverse Effects Attributable to ?-Lactam Antibiotics: A Literature Review, Drug Saf, vol.40, issue.12, pp.1171-98, 2017. ,
Cefepime-induced encephalopathy with triphasic waves in three Asian patients, Ann Acad Med, vol.36, issue.6, pp.450-451, 2007. ,
Association of antibiotics with status epilepticus ,
, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.34, issue.3, pp.327-358, 2013.
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA, vol.302, issue.21, pp.2323-2332, 2009. ,
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, Intensive Care Med, vol.39, issue.2, pp.165-228, 2012. ,
,
, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, vol.315, issue.8, pp.801-811, 2016.
Defining Septic Shock-Reply, JAMA, vol.316, issue.4, pp.456-456, 2016. ,
The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care, vol.17, p.65, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00873494
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, The ACCP/SCCM Consensus Conference Committee, vol.101, pp.1644-55, 1992. ,
Septic shock, Lancet Lond Engl, vol.365, issue.9453, pp.63-78, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-02159416
Immunosuppression in patients who die of sepsis and multiple organ failure, 31. van der Poll T, Opal SM, vol.306, pp.2594-605, 2008. ,
Choosing an antibiotic on the basis of pharmacodynamics, Ear Nose Throat J ,
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice, J Infect Dis, vol.147, issue.5, pp.910-917, 1983. ,
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.26, issue.1, pp.11-13, 1998. ,
DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic, BMC Infect Dis, vol.12, p.152, 2012. ,
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo, Antimicrob Agents Chemother, vol.51, issue.9, pp.3449-51, 2007. ,
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients, Diagn Microbiol Infect Dis, vol.48, issue.2, pp.125-155, 2004. ,
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections, Int J Antimicrob Agents, 2008. ,
Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis, J Antimicrob Chemother, vol.63, issue.3, pp.564-571, 2009. ,
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.56, issue.2, pp.498-509, 2013. ,
Augmented renal clearance and therapeutic monitoring of ?-lactams, Int J Antimicrob Agents, vol.45, issue.4, pp.331-334, 2015. ,
Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization, Curr Opin Pharmacol, vol.24, pp.1-6, 2015. ,
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients, Clin Pharmacokinet, vol.50, issue.2, pp.99-110, 2011. ,
Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of ?-lactams, Antimicrob Agents Chemother, vol.57, issue.12, p.206, 2011. ,
Prospective determination of serum ceftazidime concentrations in intensive care units, Ther Drug Monit ,
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients, Clin Pharmacokinet, vol.47, issue.7, pp.449-62, 2008. ,
Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring, Minerva Anestesiol, 2014. ,
Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin, Clin Biochem, vol.43, issue.6, pp.589-98, 2010. ,
Population pharmacokinetics of four ?-lactams in critically ill septic patients comedicated with amikacin, Clin Biochem, vol.45, pp.780-786, 2012. ,
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial, Intensive Care Med, vol.40, issue.3, pp.380-387, 2014. ,
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients, Burns J Int Soc Burn Inj, vol.41, issue.5, pp.956-68, 2015. ,
Impact of ?-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy, Int J Antimicrob Agents, vol.49, issue.5, pp.589-94, 2017. ,
Daily serum piperacillin monitoring is advisable in critically ill patients, Int J Antimicrob Agents, vol.35, issue.5, pp.500-503, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00578296
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept, Int J Antimicrob Agents, vol.36, issue.4, pp.332-341, 2010. ,
Assays for therapeutic drug monitoring of ?-lactam antibiotics: A structured review, Int J Antimicrob Agents, vol.46, issue.4, pp.367-75, 2015. ,
Measurement of meropenem concentration in different human biological fluids by ultra-performance liquid chromatography-tandem mass spectrometry, Anal Bioanal Chem, vol.406, issue.20, pp.4997-5007, 2014. ,
The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents, Adv Drug Deliv Rev, vol.77, pp.3-11, 2014. ,
Preparing and administering injectable antibiotics: How to avoid playing God, Med Mal Infect, 2016. ,
Elevated ?-lactam concentrations associated with neurological deterioration in ICU septic patients, Minerva Anestesiol, vol.81, issue.5, pp.497-506, 2015. ,
Simultaneous Determination of 12 ?-Lactam Antibiotics in Human Plasma by High-Performance Liquid Chromatography with UV Detection: Application to Therapeutic Drug Monitoring?, Antimicrob Agents Chemother, vol.55, issue.10, pp.4873-4882, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00875271
Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study, J Crit Care, vol.52, pp.75-84, 2019. ,
?-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia, Int J Antimicrob Agents, vol.41, issue.2, pp.162-168, 2013. ,
Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion, J Crit Care, vol.48, pp.66-71, 2018. ,
,
, Augmented renal clearance, low ?-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study, Int J Antimicrob Agents, vol.45, issue.4, pp.385-92, 2015.
Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients, Intensive Care Med, vol.32, issue.12, pp.2063-2069, 2006. ,
FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, vol.21, 2017. ,
, Clin Pharmacokinet, vol.52, issue.1, pp.1-8, 2013.
Changes in plasma protein binding have little clinical relevance ,
, Clin Pharmacol Ther, vol.71, issue.3, pp.115-136, 2002.
,
, Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.23, issue.7, pp.454-463, 2017.
Prospective monitoring of cefepime in intensive care unit adult patients, Crit Care Lond Engl, vol.14, issue.2, p.51, 2010. ,
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function, Antimicrob Agents Chemother, vol.54, issue.10, pp.4360-4367, 2010. ,
Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome, Crit Care Med, vol.31, issue.2, pp.462-469, 2003. ,
Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study, Ther Drug Monit, vol.34, issue.2, pp.160-164, 2012. ,
BetaLactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, vol.42, issue.10, pp.1535-1580, 2016. ,